Table 1.
Characteristic | −cGVHD* (N = 28) | +cGVHD (N = 20) | P value |
---|---|---|---|
Median age, year (range) | 58 (21-73) | 51 (28-67) | .39 |
Sex, no. (%) of females | 8 (40) | 14 (50) | .57 |
Median time after transplant, mo (range) | 23 (10-110) | 25 (12-116) | .96 |
Conditioning regimen (%) | |||
Myeloablative | 15 (54) | 6 (30) | .14 |
Nonmyeloablative | 13 (46) | 14 (70) | |
Source of graft (%) | |||
Peripheral blood | 26 (93) | 18 (90) | 1.00 |
Bone marrow | 2 (7) | 2 (10) | |
HLA matching (%) | |||
Matched, unrelated | 8 (29) | 10 (50) | .15 |
Matched, related | 18 (64) | 7 (35) | |
Mismatched | 2 (7) | 3 (15) | |
Immunosuppressive treatment (%)† | |||
Prednisone ≤30 mg (2.5-30 mg)/day | 4 (14) | 12 (60) | .002 |
MMF | 0 (0) | 1 (5) | .42 |
Tacrolimus | 5 (18) | 6 (30) | .49 |
Rapamycin | 3 (15) | 0 (0) | .07 |
ATG | 5 (18) | 4 (20) | 1.00 |
Alemtuzumab | 2 (7) | 0 (0) | .50 |
aGVHD | |||
Grade I, no. (%) | 7 (25) | 8 (40) | .74 |
Grade II, no. (%) | 2 (7) | 1 (5) | |
Grade III, no. (%) | 1 (4) | 0 (0) | |
Disease (%) | |||
AML / AML from MDS | 14 (50) | 9 (45) | |
ALL | 2 (7) | 2 (10) | |
CML | 1 (4) | 0 (0) | |
CLL | 2 (7) | 4 (20) | .81 |
MDS | 4 (14) | 2 (10) | |
NHL | 1 (4) | 2 (10) | |
MM | 1 (4) | 0 (0) | |
AA | 2 (7) | 0 (0) | |
HL | 1 (4) | 1 (5) |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma.
Included 22 patients who had never developed cGVHD and 6 patients with resolved or inactive cGVHD on date of sample collection.
On date of sample collection.